Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy

Journal of Investigative Dermatology

Volumn 114, Issue 5, 2000, Pages 928-934

  Cho, Daeho ^c   Kim, Tai Gyu ^c   Lee, Wangjae ^a   Hwang, Young Il ^a   Cho, Hyun Il ^c   Han, Hoon ^c   Kwon, Ohchan ^c   Kim, Daejin ^a   Park, Hyunjeong ^c   Houh, Dong ^b  

^a Seoul National University   (South Korea)

^b Hallym University   (South Korea)

^c NONE

Author keywords

Anti tumor effect; B7 1; Immunotherapy; Interleukin 18; Melanoma

Indexed keywords

B7 ANTIGEN; CD3 ANTIGEN; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 18;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; INTERFERON PRODUCTION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0001543990     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jid.5600685     Document Type: Article

References (18)

1. Chambers BJ, Salcedo M, Ljunggren HG: Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 5(4):311-317, 1996
2. Chen L, Ashe S, Brady WA, et al: Costimulation of anti-tumor immunity by the B7 counterreceptor for the T lymphocytes molecules CD28 and CTLA-4. Cell 71:1093, 1992
3. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE: Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179:523-532, 1994
4. Coughlin CM, Wysocka M, Kurzawa HL, Lee W, Trinchieri G, Eck SL: B7-1 and interleukin 12 synergistically induce effective anti-tumor immunity. Cancer Res 55:4980-4987, 1995
5. Geldhof AB, Moser M, Lespagnard L, Thielemans K, De Baetselier P: Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood 91:196-206, 1998
6. Giovarelli M, Cofano F, Vecchi A, Forni M: Interferon-activated tumor inhibition in vivo: small amounts of interferon-gamma inhibit tumor growth by eliciting host systemic immunoreactivity. Int J Cancer 37:141, 1986
7. Gu Y, Kuida K, Tsutsui H, et al: Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science 275:206, 1997
8. Kohno K, Kataoka J, Ohtsuki T, et al: IFN-γ -inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol 158:1541, 1997
9. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 153:421-428, 1994
10. Linsely PS, Ledbetter JA: The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11:191, 1993
11. Micallef MJ, Ohtsuki T, Kohno K, et al: Interferon-γ-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-γ production. Eur J Immunol 26:1647, 1996
12. Nastala CL, Edington HD, McKinney TG, et al: Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153:1697, 1994
13. Okamura H, Tsutusui H, Komatsu T, et al: Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378:88, 1995
14. Rosenberg SA, Mulè JJ, Spiess PJ, Reichert CM, Schwarz SL: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161:1169, 1985
15. Sun WH, Kreisle RA, Phillips AW, Ershler WB: In vivo and in vitro characteristics of interleukin 6-transduced B16 melanoma cells. Cancer Res. 52(19):5412-5415, 1992
16. Tadashi O, Péron J, Cai Q, et al: IFN-γ-inducing factor/IL-18 administration mediates IFN-γ-and IL-12-independent anti-tumor effects. J Immunol 160:1742-1749, 1998
17. Trinchieri G: Biology of natural killer cells. Adv Immunol 47:187, 1989
18. Zheng LM, Ojcius DM, Garaud F, et al: Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 184:579-584, 1996